Epidemiology |
• What is the diabetes burden in those with HFrEF and HFpEF? |
• What is the link between advanced HF and diabetes risk? |
• What is the distribution of T1D vs. T2D among people with HF? |
• What are the impacts of HF on clinical trajectories in people with prediabetes, T1D, and T2D? |
• What is the impact of new therapies on rates of developing HF? |
Mechanisms |
• What are the mechanisms contributing to the excess HF risk in certain groups with diabetes, such as people with T1D and women? |
• Are there race-specific mechanisms for HF risk? |
Care and management |
• What are the best HF prevention strategies for people with T1D and T2D? |
• What is the optimal approach to recognize and diagnose diabetic cardiomyopathy in clinical care? |
• What are the optimal approaches to manage diabetic cardiomyopathy? |
• Are there potential benefits of statins in reducing HF risk in T1D? |
• Is high-intensity statin therapy as effective in reducing HF risk as in reducing MACE? |
• Do SGLT2i confer a benefit in people with HFpEF similar to that seen in people with HFrEF? |
• What are the HF clinical trajectories across the spectrum of dysglycemia? |
• Are there additional benefits for HF in using SGLT2i-metformin or SGLT2i–GLP1-RA combinations? |
• How to best achieve optimal titration of evidence-based GDMT in daily clinical care? |
• What is the role of SGLT2i in HF outcomes in individuals with T1D? |
• Should SGLT2i be started during hospitalization with acute HF? |
• What are the optimal CGM-mHealth programs for those with diabetes and HF? |
Equity, diversity, and inclusion |
• Are sex-specific prevention and treatment approaches needed? |
• What are the best tools and strategies to address the impacts of SDOH in people with diabetes and HF? |
• How to best implement exercise programs across the entire spectrum of racially and socioeconomically diverse populations? |
Epidemiology |
• What is the diabetes burden in those with HFrEF and HFpEF? |
• What is the link between advanced HF and diabetes risk? |
• What is the distribution of T1D vs. T2D among people with HF? |
• What are the impacts of HF on clinical trajectories in people with prediabetes, T1D, and T2D? |
• What is the impact of new therapies on rates of developing HF? |
Mechanisms |
• What are the mechanisms contributing to the excess HF risk in certain groups with diabetes, such as people with T1D and women? |
• Are there race-specific mechanisms for HF risk? |
Care and management |
• What are the best HF prevention strategies for people with T1D and T2D? |
• What is the optimal approach to recognize and diagnose diabetic cardiomyopathy in clinical care? |
• What are the optimal approaches to manage diabetic cardiomyopathy? |
• Are there potential benefits of statins in reducing HF risk in T1D? |
• Is high-intensity statin therapy as effective in reducing HF risk as in reducing MACE? |
• Do SGLT2i confer a benefit in people with HFpEF similar to that seen in people with HFrEF? |
• What are the HF clinical trajectories across the spectrum of dysglycemia? |
• Are there additional benefits for HF in using SGLT2i-metformin or SGLT2i–GLP1-RA combinations? |
• How to best achieve optimal titration of evidence-based GDMT in daily clinical care? |
• What is the role of SGLT2i in HF outcomes in individuals with T1D? |
• Should SGLT2i be started during hospitalization with acute HF? |
• What are the optimal CGM-mHealth programs for those with diabetes and HF? |
Equity, diversity, and inclusion |
• Are sex-specific prevention and treatment approaches needed? |
• What are the best tools and strategies to address the impacts of SDOH in people with diabetes and HF? |
• How to best implement exercise programs across the entire spectrum of racially and socioeconomically diverse populations? |